FDA

The US Food and Drug Administration (FDA) has granted approval for Actavis’s Viberzi (eluxadoline) as a twice-daily and oral treatment for adults suffering from irritable bowel syndrome with diarrhoea (IBS-D).

IBS-D is a functional bowel disorder, which is characterised by chronic abdominal pain and frequent diarrhoea.

Viberzi is an orally active compound for treating IBS-D in men and women. With mixed opioid receptor activity, Viberzi is a mu receptor agonist, delta receptor antagonist and kappa receptor agonist.

"The FDA’s approval of Viberzi is the first step to providing physicians with a new, evidence-based, treatment option for their adult patients with IBS-D."

Actavis global brands R&D executive vice-president David Nicholson said: "The FDA’s approval of Viberzi is the first step to providing physicians with a new, evidence-based, treatment option for their adult patients with IBS-D.

"At Actavis, we are dedicated to providing new treatment options, and the development of new agents that help address the most bothersome symptoms of IBS-D."

Viberzi’s efficacy was proved in two Phase III clinical studies, which demonstrated significant superiority over placebo on the composite endpoint of simultaneous improvement in both abdominal pain and diarrhoea at both 75mg and 100mg twice-daily doses.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The primary efficacy responder endpoint was assessed over the duration of double-blind and placebo-controlled treatment.

According to the company, response rates were compared based on patients who met the daily composite response criteria for at least 50% of the days from weeks one to 12 (FDA endpoint) and weeks one to 26 (European Medicines Agency endpoint).


Image: Actavis Biologics Ltd, Estuary Banks, Liverpool. Photo: courtesy of Rept0n1x.